Basic Information
CytoDyn is committed to improving patients' lives by targeting specific drugs. Our team is focused on developing Leronlimab, a monoclonal antibody CCR5 receptor antagonist, as a platform drug for various indications.
CytoDyn Inc.
Vancouver,Washington,United States of America
less than 15 people
January 01, 2002
info@cytodyn.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios